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.a b s t r a c t
Tobacco smoke exerts perturbations on lipid metabolism and arterial cell function that accelerate
atherosclerosis. Lipidomics has emerged as a key technology in helping to elucidate the lipid-related
mechanisms of atherosclerosis. In this study, we investigated the effects of smoking cessation on pla-
que development and aortic arch content of various lipid molecular classes and species. Apolipoprotein
E-deﬁcient mice were exposed to fresh air (sham) or to mainstream cigarette smoke (CS) for 6 months, or
to CS for 3 months followed by sham for 3 months (cessation group). Lipids from plasma and aortic
arches, plasma lipoprotein proﬁles and plaque morphometry measurements were analyzed. We already
showed that CS exposure accelerated plaque size and total cholesterol content of the aortic arch at 3 and
6 months. Marked increases were seen in the relative enrichment of cholesteryl esters, phospholipids,
sphingomyelins, and glycosphingolipids. Smoking cessation slowed plaque progression and resulted in
lower levels of many lipid species in plasma and aortic arch. While CS exposure promoted rapid lipid
accumulation in mouse aorta, smoking cessation translated into a slow removal of lipids from the vessel
wall. Despite the smoking cessation-dependent metabolic changes leading to increased animal body
weight, accumulation of proatherogenic lipids in the vessel was halted after exposure cessation, indi-
cating that the clinical beneﬁts of smoking cessation translate directly to the vessel wall and its lipid
makeup.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction the enhanced levels of the high-density lipoprotein (HDL) fractionEpidemiological studies of diverse populations have shown that
cigarette smoking is a risk factor for the development of coronary
and peripheral vascular disease [1,2]. Smoking cessation results in a
rapid decline of cardiovascular risk within the ﬁrst 5 years as re-
ﬂected by inﬂammatory markers and traditional risk factors [3].
The partially reversible nature of the atherogenic effects of smoking
appears to be due to an improvement in lipid proﬁle, as reﬂected by: þ41 58 242 2811.
).
.r Ltd Open access under CC BY-NC-SAreported after smoking cessation [4].
Notwithstanding the established association of low-density li-
poprotein (LDL) and HDL with cardiovascular risk, a proportion of
patients that exhibit plasma levels of LDL and HDL within clinically
recommended ranges develop coronary artery disease [5]. This
residual risk suggests that lipids other than the conventional clas-
ses measured in the clinical setting are involved in atherogenesis
and require additional diagnostic tools for their identiﬁcation.
Molecular lipidomics was used in this study to address the question
of which other lipids may play key roles in vascular disease pro-
gression. The recent development of mass-spectrometry-based
methods to resolve complex lipid components [6], is having
a profound effect on current approaches to analyzing the patho-
physiological role of lipid species that, up to now, may have had
unsuspected roles in vascular lesion formation. A solid license .
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lecular species within the atherosclerotic plaque is an essential step
to elucidating the comprehensive molecular decoding required to
promote the arterial efﬂux of harmful lipid species.
Using smoke exposure as an inducer of vascular dysfunction in
apolipoprotein E-deﬁcient (ApoE/) mice, a well-established
model for human atherosclerosis [7], we have previously shown
speciﬁc smoking-induced changes in the vascular lipidome
including accumulation of ceramides, cholesteryl esters (CE) and
phosphatidylcholine (PC) species [8]. We are now reporting addi-
tional plasma and tissue lipidomics data from a smoking cessation
group of mice included in our original experimental design, and
compare them to data from the sham exposure and continuous
smoking groups. Plasma total cholesterol (TC), LDL, HDL, and very
low-density lipoprotein (VLDL) were measured by high perfor-
mance liquid chromatography (HPLC); shotgun and targeted lip-
idomics were utilized to identify additional lipid classes (e.g.,
phospholipids, glycolipids) in mouse plasma and aorta. Our previ-
ous data indicated that multiple plasma and tissue lipid species
were affected in animals exposed to mainstream cigarette smoke
(CS) from a standard reference cigarette (3R4F) [8]. Compared to
that continuous smoking group of animals, the smoking cessation
results reported here are consistent with lower plasma levels of
lipid species from all classes examined. Smoking cessation also
hindered the CS-dependent retention rates of proatherogenic lipid
classes in vascular tissue. Despite a faster body weight increase
after smoking cessation compared to continuous smoking,
decreased levels of most lipids were observed in both plasma and
vascular tissue after only three months of cessation.
2. Methods
Most methods used have been described in detail in Ref. [8]. A
summary of the material and methods is given below.
2.1. Experimental design
ApoE/ mice fed a normal laboratory diet containing 0.003%
cholesterol and 4.0% fat (Harlan Teklad 2014, Harlan, Oxon UK)
were exposed to ﬁltered fresh air (sham group) or tomainstream CS
for 3 and 6months (continuous smoking group, CS) or for 3 months
only and then switched to sham exposure for 3 additional months
(cessation group). Data from the sham and CS groups were previ-
ously reported [8]; for comparison purposes, they are also included
in this report. The protocol was designed to model the effects of
smoking cessation (Supplementary Fig. S1). Seven to eight mice
were used for lipid measurements in plasma and aorta, 16 for
plaque size measurements, and 6e8 for lipidomics.
2.2. Animals, smoke generation and exposure
All animal experimental procedures were in conformity with
the AALAS Policy on the Humane Care and Use of Laboratory Ani-
mals (AALAS, 1996) and were approved by the Institutional Animal
Care and Use Committee (IACUC, Leuven, Belgium). Female ApoE/
 (Apoe/Bom, B6.129P2-Apoetm1UncN11) mice aged 5e9 weeks were
obtained from Taconic (Denmark). The Reference Cigarette 3R4F
was obtained from the Tobacco Research and Development Center
(University of Kentucky, KY, USA). The cigarettes were conditioned
according to ISO standard 3402 (ISO, 1999) as previously described
[9]. Other smoking parameters including puff duration and volume
were conducted in conformity with the Health Canada Intense
(HCI) smoking regimen [10]. Total particulate matter (TPM) levels
for smoke exposure were targeted at 600 mg/l; animals were
exposed for 3 h per day. Carboxyhemoglobin (COHb) plasma levelswere determined as a marker of smoke uptake at 3 and 6months as
described elsewhere [9].
2.3. Cholesterol and lipoprotein measurement in serum and aorta
Aliquots of plasma were analyzed using commercial kits from
Thermo Clinical Labsystems (Frankfurt, Germany) according to
manufacturer’s instructions. Planimetry data from the aortic arch
were used for normalization and the cholesterol concentrations are
given in nmol/mm2 aorta.
2.4. Atherosclerotic plaque measurements in the aortic arch
Mice were anesthetized, exsanguinated, and perfused with ice-
cold PBS. After careful removal of the aortic arch with the aid of a
dissecting microscope, tissue was opened longitudinally and ﬁxed
with dissecting pins. Pictures of the opened vessel were takenwith
a TBK Digital camera KY-F70 (Leica) and images were analyzedwith
DISKUS image analysis software (Hilgers, Koenigswinter, Ger-
many). The intimal area covered by plaques was determined and
normalized to the whole aortic arch area.
2.5. Lipidomics analysis
Molecular lipids from plasma and homogenized aortic arches
were extracted and quantiﬁed by Zora Biosciences (Espoo, Finland)
using synthetic non-endogenous standards as described in Ref. [8].
Lipids were normalized to their respective internal standard and
the sample volume or tissue weight. The concentrations of mo-
lecular lipids are presented as mM for plasma and nmol/mg wet
tissue for aortic samples. A table with the number of all lipid species
per class is available in the online Data Supplement (Table S1).
Concentrations measured are reported in Supplementary Excel File.
2.6. Statistical analysis
Data are expressed asmean standard error of the mean (SEM),
unless otherwise indicated. Differences between group means for
non-lipidomics data (plasma lipoproteins, plaque area and aortic
TC) and their associated 95%-conﬁdence interval (CI), as estimated
by the Fisher’s Least Signiﬁcant Difference (LSD) method, were
obtained. All computations were performed with SAS version 9.2
(SAS Institute Inc., Cary, NC, USA). For lipidomics data, Wilcoxon
rank-sum tests were performed for pairwise comparisons and
statistical signiﬁcance (unadjusted p-value < 0.05) reported.
3. Results
Comparisons involving the smoking cessation group for the lip-
idomics endpoints were conducted against sham and continuous
smoking (CS) groups. The three groups (sham, CS, and cessation)
represent separate arms of a single experimental design with well-
deﬁned exposure and cessation protocols, as described in the
methods section and depicted in Supplementary Fig. S1. Although
we have previously reported the effects of smoke exposure as
compared to sham-exposedanimals [8], theyare summarizedbelow
to provide context to the novel ﬁndings on the effects of smoking
cessation compared to continuous smoking and sham exposure.
Plasma levels of COHb, an indicator of inhaled smoke, increased
rapidly in mice smoke-exposed (40.7  1.9% after 3- and
40.5  0.8% after 6 months of exposure). Mice in the cessation
group exhibited levels comparable to those observed in sham ani-
mals (4.9  0.2% vs. 5.1  0.2% at the 6-month time point).
Body weight. Body weight increased steadily in all groups
throughout the study (Fig. 1), however, the increase rate was
Fig. 1. Animal body weight. CS-exposed animals grew at a slower rate compared to
sham mice. Mice exposed to CS for 3 months and then switched to regular ﬁltered air
(cessation) resumed a higher growth rate and approached the weight attained by sham
animals at the end of the observation period. Data expressed as mean  SEM.
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cessation group, body weight increased rapidly after cessation of
smoke exposure at a rate similar to the sham group, however, it
remained below that of the sham group throughout most of the
cessation period.
Plasma lipoproteins. Mice in the cessation group showed
decreased levels of TC and VLDL compared to the CS group and no
signiﬁcant difference to the sham group. Plasma levels of IDL/LDL
and HDL did not differ much among the 3 groups. (Supplementary
Fig. S2 and Table S2).
Atherosclerotic plaque size. Aortic plaque area of mice in the CS
group was signiﬁcantly larger compared to sham at both 3 and 6
months (Fig. 2A and Supplementary Table S2). While mice in the
cessation group exhibited a smaller plaque area than mice in the
continuous smoking group, plaque area was still signiﬁcantly
higher compared to sham. Representative histopathological images
of aortic plaque areas for each group are shown in Fig. 2B.
Aortic cholesterol. There was a time-dependent increase in aortic
TC content in smoke-exposed mice. Mice in the cessation group
exhibited remarkably lower levels (51%) of TC compared to mice in
the CS group, although TC concentrations in vascular tissue
remained signiﬁcantly higher compared to mice in the sham group.
Effects of smoking cessation on plasma lipids. Cessation compared
to Sham (Fig. 3, left panel, gray bars). The same trend was observed
for most lipid species in the cessation group, namely a reduction of
lipid concentrations compared to sham, although only a few spe-
cies, phosphatidylcholine (PC), plasmalogens (PC P), sphingomyelin
(SM), sphinganine-1-P (SA1P), and globotriasylceramide (Gb3)
showed signiﬁcant reductions.
Glucosyl/galactosylceramide [Glc/GalCer], other neutral GSLs,
and sphinganine remained virtually unchanged after the 3-
month smoking cessation period. Cessation compared to CS
(Fig. 3, right panel, gray bars). Similarly, the plasma levels of the
vast majority of molecular lipid species including FC, CE, glycer-
olipids (except TAG), phospholipids (except PE P), sphingolipids,
and GSL (cerebrosides, gangliosides and sulfatides) were lower in
the cessation group when compared to the CS group. Results
were statistically signiﬁcant for FC, PC, PC P, phosphatidylinositol
(PI), SM, sphingosine-1-P (S1P), SA1P, Gb3, monosialoganglioside
1 (GM1), and sulfatides (SGalCer). CS compared to Sham (Fig. 3,
left panel, dark bars). Changes in CS group compared to sham
were almost always opposite to that of the cessation group,
namely showing a trend to increased lipid concentrations (sig-
niﬁcant for S1P), except for CE, TAG and Gb3 which tended to
exhibit lower concentrations.Effects of smoking cessation on aortic arch tissue lipids. Smoking
Cessation compared to Sham (Fig. 4, left panel, gray bars) Compared
to sham, the cessation group exhibited higher levels of all lipid
classes (CE, glycerolipids, phospholipids, Cer and GSL) and signiﬁ-
cant increases in 11 lipid species including CE, DAG, PC, PC P, LPC,
LPE, PI, PS, SM, Cer, and Glc/GalCer. Smoking Cessation compared to
CS (Fig. 4, right panel, gray bars). The levels of all lipids measured,
except for DAG and PE, were slightly lower in the cessation group
compared to CS, the continuous smoking group. Nonetheless, re-
sults were statistically signiﬁcant only for alkyl-linked PC O (PC O)
and increased levels of DAG. Absolute concentrations of all lipid
classes measured in aortic tissue are shown in Supplementary
Fig. S4. CS compared to Sham (Fig. 4, left panel, black bars). CE
was signiﬁcantly elevated, especially CE 18:1, CE 18:2, CE 16:0, CE
20:4, CE 22:4 (Supplementary Fig. S3). All phospholipid classes
were also higher; results were statistically signiﬁcant for all except
PE and PE P. SM, Cer, Glc/GalCer, and LacCer concentrations were
signiﬁcantly higher.
4. Discussion
Changes in lipid metabolism are at the center of the extensive
metabolic effects induced by cigarette smoking [11]. A proathero-
genic lipid proﬁle is thought to be responsible for the increased
incidence of cardiovascular disease in smokers [12]. We previously
demonstrated that exposure to CS for 12 months accelerates the
development of atherosclerosis in ApoE/ mice [13] and that this
effect is accompanied by speciﬁc changes in the vascular lipidome
[8]. To further our knowledge on the effects of smoking cessation,
we sought to determine the effects of switching from cigarette
smoke exposure to sham exposure on plaque development and
lipid accumulation in the vessel wall of ApoE/ mice. The high
inﬂammation baseline level exhibited by ApoE/ mice was a pri-
mary consideration in choosing this strain. The ApoE-deﬁcient
mouse also exhibits altered lipid clearance mechanisms that may
play a key role in accumulation of lipids in the vessel wall.
Although, the wild type control strain (C57BL/6) also develops
atherosclerosis when fed a high fat diet [14], our study design solely
focused on the effects of CS and cessation under a normal chow
diet. Threemonths of smoking cessation resulted in a slower plaque
growth rate compared to continuous smoke exposure (Fig. 2).
Although changes in plasma concentrations of TC were marginal,
cholesterol content in the vessel wall of CS-exposed mice increased
over time, as we previously reported [8], whereas smoking cessa-
tion resulted in lower aortic TC levels (w50% of the 3R4F group) and
a concomitant smaller size of the atherosclerotic plaque (Fig. 2).
Consistent with the aortic determinations of cholesterol by HPLC,
higher levels of CE measured by mass spectrometry were also
found in aortic tissues of CS-exposed mice [8]. Smoking cessation
resulted in decreased levels of most molecular species of CE
including those that we found previously increased in plasma, liver
and aorta of CS-exposed animals (CE16:1, CE18:1 and CE18:3) [8]
(Supplementary Fig. S3). Taken together, these results indicate
that plasma concentrations of total cholesterol and CE are limited
indicators of CS-induced cholesterol retention and plaque growth,
pointing at the need for additional, more sensitive surrogates of
disease progression.
Animal body weight increased steadily after smoking cessation
began (Fig. 1). Unlike the profound CS- and cessation-mediated ef-
fects on plasma lipoproteins reported in humans [15], lipid meta-
bolism changes associated to bodyweight increase in ApoE/mice
were not paralleled by changes in conventional plasma lipoproteins.
Species-speciﬁc differences in the distribution of ApoB48, ApoB100
and ApoE in lipid particles, as well as tissue-speciﬁc receptor-
mediated lipoprotein particle uptake may have contributed to the
Fig. 2. Plaque morphometric analysis. A. CS exposure discontinuation (cessation) resulted in a signiﬁcantly smaller plaque size when compared to plaque areas from CS. However,
plaque area in these aortas was still higher than plaque areas from aortas of sham mice. B. Representative images of each group at 3 and 6 months are shown. C. TC content in aortic
tissue. Mice from the cessation group exhibited lower levels of TC compared to CS-exposed animals, although the level at 6 months was still higher than in sham-exposed mice. *:
95%-CI of difference to sham does not contain 0; #: 95%-CI of difference to continuous smoking does not contain 0. Data expressed as mean  SEM.
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tissues of the smoking cessation group showed lower content trends
compared to both sham and CS groups, stressing the reversible na-
ture of the vascular effects of CS. Plasma concentrations of various
lipid classes (e.g., FC, PC, PI, and SM) were lower in animals under
smoking cessation conditions compared to their CS-exposed coun-
terparts, whereas most lipid classes in aortic tissues exhibited less
dramatic reductions. These ﬁndings suggest that the dynamics
encompassing reaction kinetics and mechanisms regulating inﬂux/
efﬂux of lipid species in vascular tissue (e.g., rates of synthesis and
degradation, cell transporters) were affected differently by CSexposure and smoking cessation. CS exposurepromoteda rapid lipid
accumulation and smoking cessation translated into a slow removal
of lipids from the vessel wall. Larger observation periods would be
necessary to ascertain whether the vascular lipidome returns to a
proﬁle similar to sham-exposed animals.
Similar to our ﬁndings in ApoE/ mice, C57BL/6 mice fed
acrolein, a component of CS, showed increased levels of VLDL with
little change in LDL and HDL and a shift toward increased choles-
terol content in VLDL [16]. Plasma and tissue cholesterol levels, as
determined by mass spectrometry in the current work, were also
higher in CS-exposed ApoE/ mice. The largest lipoprotein
Fig. 3. Plasma lipidomics at 6 months of CS exposure. Data are expressed as percent change compared to a reference group; three comparisons are shown. Black bars represent
percent change of lipid classes in the CS group compared to the sham group. Dark gray bars on the left panel represent percent change in the cessation group compared to sham.
Light gray bars on the right panel compared cessation vs. CS groups. Lipid classes within each representative group were signiﬁcantly smaller after smoking cessation in comparison
to the CS group, whereas only sphingosine-1-P levels were signiﬁcantly higher in the CS group compared to the sham group. Multiple molecular species were lower in the cessation
group when compared to the CS group. (*: p < 0.05).
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accounts for the large increase in plasma cholesterol levels [17]. The
higher CS-induced plasma VLDL concentrations that we observed
in ApoE/mice may be due to an increase in hepatic synthesis or a
decrease in lipoprotein uptake. Since mice do not express CETP [18]
and VLDL is a poor substrate of lecithin:cholesterol acyltransferase,
nascent hepatic TG-rich particles that become cholesterol ester-
rich particles is unlikely in ApoE/ mice [17]. Diminished
receptor-mediated VLDL clearance secondary to lack of ApoE in
VLDL particles is a more viable hypothesis as ApoB48-containing
particles in rodents are fully dependent on ApoE for receptor-
mediated uptake.
Simultaneous murine deﬁciencies of SM synthase (SMS) and
ApoE (Sms2//ApoE/) result in reductions of plasma SM levels
and atherosclerotic lesion size [19], highlighting the atherogenic
impact of SM, an abundant phospholipid present in most circu-
lating lipoproteins. SM was retained in aortic tissue in response to
CS-exposure and plasma levels were lower in the cessation group
compared to the CS-exposed group. We have previously
demonstrated increased levels of GSL in aortic tissue of CS-
exposed ApoE/ mice [8]. Our earlier ﬁndings provided evi-
dence that GSL neutral species, Glc/GalCer and LacCer, were
enriched in aortas of CS-exposed ApoE/ mice [8], whereas tis-
sue levels of gangliosides (GM1, GM3, Gb3) remained unchanged,
drawing attention to the preferential perturbations of CS on
arterial lipid retention, particularly on driving the de novo syn-
thesis of ceramides and SM (Fig. 5), both proatherogenic lipid
classes. Notwithstanding that Glc/GalCer, LacCer and SM were alllower in the cessation group compared to the CS group, decreased
levels were not signiﬁcant, suggesting that these complex mole-
cules may have a slow vascular turnover rate. LacCer has been
shown to act as a lipid second messenger that induces cell pro-
liferation through NADPH and superoxide (O2) generation in
vascular smooth muscle cells [20,21]. The long-term clinical
beneﬁts of smoking cessation in terms of decreased cardiovas-
cular risk may be mechanistically accounted for by reduced
retention rates of ceramides, SM and other proatherogenic spe-
cies, resulting in a vascular lipid proﬁle with a weakened
atherogenic potential.
In mammalian cells, TAG are neutral lipids that function as
energy reserves, whereas DAG are intermediates in phospho-
lipid biosynthesis and act as signaling molecules. DAG concen-
trations were slightly larger in aortas of CS-exposed mice (þ6%),
but they were notably higher in aortas of mice that were
switched to a cessation protocol (þ78%). Aortic DAG may be
generated by hydrolysis of phosphatidic acid (PA), PC, or PE. We
hypothesize that the cessation-mediated increased levels of
DAG were due to the increased substrate availability provided
by PC, PS, plasmalogens (PC P, PC O), LPC, and LPE, all of which
were augmented by CS exposure and reduced upon cessation
(Supplementary Fig. S5). Alternatively, inhibition of diac-
ylglycerol acyltransferase (DGAT), diacylglycerol kinase (DAGK),
or increased uptake from the circulation may also result in
arterial DAG accumulation. LPC is generated from PC by
lipoprotein-associated phospholipase A2 (Lp-PLA2) during LDL
oxidation in atherosclerotic lesions. However, an augmented
Fig. 4. Aorta lipidomics after 6 months of CS exposure. Data are expressed as percent change compared to a reference group. Black bars represent percent change of lipid classes
in the CS group compared to the sham group. Dark gray bars on the left panel represent percent change in the cessation group compared to the CS group. Light gray bars on the right
panel represent changes in the cessation group compared to the CS group. Lipid classes within each representative group were signiﬁcantly larger after CS exposure or cessation
compared to sham (left panel), whereas only ether-linked phospholipid levels (PC O) were smaller in the cessation group compared to the CS group (right panel). *: p < 0.05.
Fig. 5. Schematic representation of the biosynthetic pathways of sphingolipid and GSL metabolism (modiﬁed from a KEGG pathway). The effects of CS vs. sham and of cessation
vs. CS in aortic tissue are represented as red and green, respectively in the inset histograms. 1) Dihydroceramide synthase; 2) Galactosylceramide synthase; 3) Sphingomyelin
synthase; 4) Sphingomyelinase; 5) Galactosylceramide synthase; 6) Galactosylceramidase; 7) Glucosylceramide synthase; 8) Glucosylceramidase; 9) Lactosylceramide synthase; 10)
Beta-galactosidase.
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plasma LPC [22]. The proinﬂammatory actions of LPC are evi-
denced by its potent chemotactic effects, which seem to be
speciﬁc for circulating monocytes [23].
We have shown that LPE exhibited the largest relative increase
of all lipid species in aortas of CS-exposed ApoE/mice (þ181%),
whereas PE showed a negligible rise (þ6%) [8], suggesting that
conversion of PE to LPE is favored by exposure to CS. PI and PG
were also elevated in aortas of CS-exposed mice. PI are well
recognized lipid metabolites that act as second messengers (e.g.,
PI3K) for a variety of extracellular signals that bind to cell surface
receptors and control arterial cell functions including prolifera-
tion, apoptosis and, migration [24]. S1P was the only lipid species
that displayed signiﬁcantly higher and lower plasma levels after
CS-exposure and cessation, respectively. S1P is a bioactive lipid
with numerous functions in the immune and cardiovascular
systems. Inhibition of S1P biosynthesis with myriocin was found
to reduce the atherosclerotic plaque size in ApoE/ mice [25].
However, FTY720, an S1P analogue, has been shown to attenuate
[26] or have no effect [27] on the development of atherosclerosis
in this strain. Studies examining tissue sources, molecular trig-
gers, and downstream effects of S1P and other sphingolipids in
CS-exposed ApoE/ mice are needed to further our knowledge
and discern their mechanistic role in CS-mediated plaque
development.
A recent report on lipidomics of human endarterectomy sam-
ples revealed that many of the lipid species retained in carotid ar-
teries [28] are similar to the ones we found to be retained in the
vessel wall of ApoE/ mice including CE, LPC and SM, as we pre-
viously reported for CS-exposed animals [8]. The current report
extends those ﬁndings to the smoking cessation status, wheremost
molecular species of CE, SM and PC enriched in human plaques,
exhibited lower levels compared to CS-exposed animals
(Supplementary Fig. S6).
Study limitations. Although our study was focused on the anal-
ysis of molecular lipids, other non-lipid related cellular and mo-
lecular plaque components, including inﬂammatory cells, smooth
muscle cells and oxidative stress-related molecules are affected by
CS and contribute to atherogenesis and plaque growth [29].
Therefore, further research is warranted to simultaneously assess
the role of these non-lipid components in vascular lesion formation
rates during CS exposure and smoking cessation. Notwithstanding
that the cessation arm of the study suggests that the vascular
removal rate of numerous lipid species is slower compared to the
CS-dependent accumulation rate, a time course analysis including
smoking cessation periods beyond three months is required to fully
validate our ﬁndings and provide additional support to the trans-
latability of our ﬁndings to the human setting.
In conclusion, our ﬁndings highlight the pathophysiological
relevance and translatability of the ApoE/ mouse model of
vascular disease and the potential of murine arterial lipids to serve
as surrogates of disease progression and monitoring of drug or risk
reduction (e.g. smoking cessation) efﬁcacy.Financial disclosure
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